Study guide
12.2 Clinical Interpretation, Serial Comparison, and Reporting
ARRT Bone Densitometry Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Orientation & the ARRT Blueprint
1.1 About the ARRT Bone Densitometry Examination 1.2 Eligibility, Structured Education, and Clinical Experience
2 Chapter 2: Osteoporosis, Bone Biology & Risk Factors
2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria 2.2 Bone Functions, Structural Anatomy, and Bone Types 2.3 Bone Cells, the Remodeling Cycle, and Calcium Homeostasis 2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
3 Chapter 3: Indications, Prevention & Treatment
3.1 The Bone Mass Measurement Act: Covered Indications and Coding 3.2 Prevention: Nutrition, Exercise, Smoking Cessation, and Fall Prevention 3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
4 Chapter 4: Patient Preparation, Support & Radiation Safety
4.1 Patient Support, Disabilities, Ergonomics, and Transfer Techniques 4.2 Patient Instructions: Explaining the Exam, Dose, Duration, and Motion Control 4.3 Patient History, Contraindications, and Pregnancy Screening 4.4 Scan Preparation: Patient Data Entry, Artifact Removal, and Infection Control 4.5 Radiation Safety in DXA: ALARA, Distance, and Dose Levels
5 Chapter 5: DXA Physics & Instrumentation
5.1 Physical Principles of Dual-Energy X-ray Absorptiometry 5.2 Beam Geometries: Pencil Beam and Fan Beam Systems 5.3 Fan-Beam Geometry: Source–Object–Detector Distances, Magnification, and Centering 5.4 The Scan Analysis Algorithm: Soft Tissue, Bone Edge Detection, BMC, Area, and BMD
6 Chapter 6: Measuring & Reporting Bone Mineral Density
6.1 Statistics for Densitometry: Mean, Standard Deviation, and Coefficient of Variation 6.2 T-Scores, Z-Scores, and Reference Database Selection 6.3 Clinical Indications for BMD Testing and the FRAX Tool 6.4 Vertebral Fracture Assessment and Trabecular Bone Score 6.5 Whole Body DXA, Body Composition, and Pediatric Scanning
7 Chapter 7: Quality Control, Precision & Equipment Management
7.1 Accuracy, Precision, and the Sources of Precision Error 7.2 Daily Quality Control, Phantoms, and Control Charts 7.3 In Vivo Precision Studies and RMS-SD Calculation 7.4 Determining and Applying the Least Significant Change 7.5 Maintenance, Repair, Relocation, Cross-Calibration, and Software Upgrades
8 Chapter 8: DXA Informatics & Data Management
8.1 DXA Informatics, DICOM, PACS, and Data Management
9 Chapter 9: Lumbar Spine DXA
9.1 Lumbar Spine Anatomy, Landmarks, and Regions of Interest 9.2 Lumbar Spine Scan Acquisition and ROI Edge Placement 9.3 Lumbar Spine: Compensating for Body Habitus, Variant Anatomy, Pathology, and Low Bone Density 9.4 Lumbar Spine Positioning: The Leg Block, Centering, and Common Challenges 9.5 Lumbar Spine Problems: Poor Bone Edge Detection and Obscured Intervertebral Spaces 9.6 Lumbar Spine: Variant Anatomy, Fractures, Degenerative Pathology, Calcification, and Surgery 9.7 Lumbar Spine Analysis: Vertebral Exclusion and Reporting Rules 9.8 Lumbar Spine Follow-Up Scans and Rate of Change
10 Chapter 10: Proximal Femur DXA
10.1 Proximal Femur Anatomy, Landmarks, and Regions of Interest 10.2 Femur Selection: Right, Left, and Dual Femur Scanning 10.3 Proximal Femur Scan Parameters and Compensation 10.4 Proximal Femur Positioning: Neck Rotation, Shaft Placement, and Positioning Aids 10.5 Proximal Femur Problems: Ischium, Short Neck, Arthritis, Fracture, and Hardware 10.6 Femoral ROI Analysis: Femoral Neck, Total Hip, and Ward's Area 10.7 Proximal Femur Follow-Up Scans and Rate of Change
11 Chapter 11: Forearm DXA
11.1 Forearm Anatomy, Landmarks, and Adjacent Structures 11.2 Forearm Indications and Side Selection 11.3 Forearm Length Measurement, Scan Parameters, and Positioning 11.4 Forearm Regions of Interest: One-Third, Mid, Ultradistal, and Total 11.5 Forearm Problems: Edge Detection, Artifacts, Low Bone Density, and Joint Disease 11.6 Scan Analysis: Region Placement, Window Level, and Reported Values 11.7 Forearm Follow-Up Scans and Rate of Change
12 Chapter 12: Cross-Site Artifacts & Clinical Integration
12.1 Recognition, Impact, and Management of DXA Artifacts 12.2 Clinical Interpretation, Serial Comparison, and Reporting
12.2 Clinical Interpretation, Serial Comparison, and Reporting
Key Takeaways Explain This Topic AI
T-scores compare patient BMD to a healthy young-adult female Caucasian reference database (NHANES III) and define WHO diagnostic criteria exclusively for postmenopausal women and men aged 50 and older.
Z-scores compare patient BMD to an age-, sex-, and ethnicity-matched cohort and must be used for premenopausal women, men under 50, and pediatric patients, with scores <= -2.0 classified as 'below expected range for age.'
Serial scan monitoring requires comparing absolute areal BMD (g/cm^2) acquired on the same manufacturer's device in identical modes; changes must exceed the facility's Least Significant Change (LSC) at the 95% confidence interval to represent true biological change.
Vertebral Fracture Assessment (VFA) provides low-dose (~10–30 uSv) lateral thoracolumbar imaging (T4–L4) on the DXA table, graded using the Genant semi-quantitative visual scale (Mild 20–25%, Moderate 25–40%, Severe >40% height loss).
Trabecular Bone Score (TBS) extracts gray-level texture variations from 2D spine DXA to quantify 3D trabecular microarchitecture, independently predicting fracture risk and adjusting FRAX probabilities without additional radiation exposure.
Last updated: September 2026
12.2 Clinical Interpretation, Serial Comparison, and Reporting
Quick Answer: Central DXA interpretation requires matching statistical metrics to patient demographic groups: T-scores (derived from the young-adult female NHANES III reference database) define World Health Organization (WHO) diagnostic categories exclusively for postmenopausal women and men aged 50 and older. Z-scores (matched for age, sex, and ethnicity) must be used for premenopausal women, men under 50, and children, where a score ≤ -2.0 indicates "below expected range for age." Serial monitoring must track absolute areal BMD (g/cm²), not T-scores, requiring changes to exceed the facility's Least Significant Change (LSC) at the 95% confidence level. Advanced modalities include Vertebral Fracture Assessment (VFA, T4–L4 lateral imaging evaluated via the Genant 0–3 grading scale), Trabecular Bone Score (TBS, 2D texture analysis reflecting 3D microarchitecture), and whole-body body composition analysis.
T-Score vs. Z-Score: Mathematical Definitions and Reference Databases
Dual-energy X-ray absorptiometry measures areal bone mineral density (BMD) in grams of hydroxyapatite per square centimeter (g/cm²). Because absolute BMD varies across manufacturers due to calibration differences and beam geometries, clinical interpretation relies on standardized standard deviation (SD) scores:
The T-Score
The T-score measures the standard deviations a patient's measured BMD deviates from the mean peak bone mass of a healthy young-adult reference population: T-score = Patient Measured BMD − Young-Adult Mean BMD Young-Adult Standard Deviation (SD) \text{T-score} = \frac{\text{Patient Measured BMD} - \text{Young-Adult Mean BMD}}{\text{Young-Adult Standard Deviation (SD)}} T-score = Young-Adult Standard Deviation (SD) Patient Measured BMD − Young-Adult Mean BMD
Standard Reference Database: Under WHO and ISCD guidelines, the NHANES III female Caucasian database (ages 20 to 29) is the international standard reference database for calculating femoral neck and total hip T-scores in all postmenopausal women and all men aged 50 and older , regardless of the patient's race or ethnicity. Standardizing to a uniform female reference database provides uniform fracture risk stratification across all adult populations.
The Z-Score
The Z-score measures the standard deviations a patient's measured BMD deviates from the mean BMD of an age-, sex-, and ethnicity-matched reference population: Z-score = Patient Measured BMD − Age-Matched Mean BMD Age-Matched Standard Deviation (SD) \text{Z-score} = \frac{\text{Patient Measured BMD} - \text{Age-Matched Mean BMD}}{\text{Age-Matched Standard Deviation (SD)}} Z-score = Age-Matched Standard Deviation (SD) Patient Measured BMD − Age-Matched Mean BMD
The Z-score determines whether bone density is abnormal compared to peers of identical age, gender, and racial background.
Demographic Rules: Clinical Application of T-Scores and Z-Scores
Densitometry standards strictly govern which score can be applied to specific patient demographics:
1. Postmenopausal Women and Men Aged 50 and Older
Applicable Metric: T-Score .
Diagnostic Categories (WHO Criteria):
Normal: T-score ≥ -1.0 SD.
Low Bone Mass (Osteopenia): T-score between -1.0 and -2.5 SD (-1.1 to -2.4 SD).
Osteoporosis: T-score ≤ -2.5 SD at the lumbar spine, femoral neck, total hip, or 33% radius.
Severe (Established) Osteoporosis: T-score ≤ -2.5 SD accompanied by ≥ 1 fragility fracture.
2. Premenopausal Women and Men Under Age 50
Applicable Metric: Z-Score exclusively .
Diagnostic Rules: WHO T-score criteria cannot be applied. The terms "osteopenia" and "osteoporosis" must never be diagnosed based on densitometry alone in this group.
ISCD Reporting Terminology:
- Z-Score > -2.0 SD: Reported as "Within the expected range for age."
- Z-Score ≤ -2.0 SD: Reported as "Below the expected range for age."
Clinical Action: A Z-score ≤ -2.0 indicates bone density disproportionately low for age, mandating evaluation for secondary causes of bone loss (e.g., hyperparathyroidism, celiac disease, hypogonadism, or glucocorticoid exposure).
3. Pediatric Patients (Ages 5 to 19)
Evaluated strictly using pediatric Z-scores adjusted for age, sex, and height/size (spine and whole body less head [WBLH]).
Serial Scan Monitoring and the Least Significant Change (LSC)
Monitoring therapeutic response or tracking disease progression over time requires strict adherence to serial comparison rules:
Compare Absolute BMD (g/cm²), Never T-Scores or Z-Scores: Clinicians must never evaluate serial change by comparing T-scores or Z-scores. Reference databases, software versions, and standard deviations can shift between updates, producing artificial changes in T-scores without true biological change. True biological changes can only be determined by comparing absolute areal BMD in g/cm².
Scanner Consistency and Acquisition Mode: Serial scans must be performed on the same scanner manufacturer and model , utilizing identical scan modes and positioning protocols.
Least Significant Change (LSC): Because every physical measurement carries intrinsic precision error, an observed BMD difference does not necessarily indicate true biological change. The measured difference must exceed the facility's Least Significant Change (LSC) calculated at the 95% confidence level: LSC = 2.77 × Precision Error (Root-Mean-Square SD) \text{LSC} = 2.77 \times \text{Precision Error (Root-Mean-Square SD)} LSC = 2.77 × Precision Error (Root-Mean-Square SD)
Clinical Interpretation: If |ΔBMD| < LSC, report "No statistically significant change." If |ΔBMD| ≥ LSC, the change represents a true biological gain or loss.
ISCD Precision Limits: Lumbar spine RMS-SD ≤ 1.9% (LSC ≤ 5.3%); Total hip RMS-SD ≤ 1.8% (LSC ≤ 5.0%); Femoral neck RMS-SD ≤ 2.5% (LSC ≤ 6.9%).
Vertebral Fracture Assessment (VFA)
Vertebral fractures are the hallmark of osteoporosis, yet up to two-thirds remain clinically silent. Vertebral Fracture Assessment (VFA) captures low-dose single- or dual-energy lateral thoracolumbar images (T4 through L4) directly on the DXA table:
Radiation Dose: Delivers an ultra-low effective dose of 10 to 30 µSv (roughly 1% of standard spine radiography at ~1,500 to 2,000 µSv).
Clinical Significance: Identifying an unrecognized vertebral fracture immediately reclassifies an osteopenic patient as having severe osteoporosis , warranting bone-active pharmacotherapy regardless of T-score.
Genant Semi-Quantitative Visual Scale: Quantifies vertebral height loss compared to adjacent intact vertebrae:
Grade 0 (Normal): < 20% height loss.
Grade 1 (Mild): 20% to 25% vertebral height reduction; 10% to 20% area reduction.
Grade 2 (Moderate): 25% to 40% vertebral height reduction; 20% to 40% area reduction.
Grade 3 (Severe): > 40% vertebral height and area reduction.
Deformity Types: Wedge (anterior collapse), biconcave (middle collapse), and crush (entire body collapse).
Trabecular Bone Score (TBS)
Central DXA measures 2D projected density but cannot assess internal trabecular connectivity. Trabecular Bone Score (TBS) is an advanced gray-level texture analysis tool that evaluates 3D bone microarchitecture from raw lumbar spine DXA scans:
Underlying Principle: TBS applies a modified variogram algorithm to quantify gray-level amplitude variations between adjacent pixels across L1–L4 raw scan data. High TBS indicates dense, well-connected trabeculae; low TBS indicates porous, fragmented microarchitecture.
Zero Additional Radiation: TBS is calculated directly from existing PA spine DXA files without requiring additional scans or radiation exposure.
Fracture Prediction and FRAX: TBS independently predicts fragility fractures (especially in type 2 diabetes and glucocorticoid exposure where BMD appears deceptively normal) and adjusts 10-year fracture probabilities within FRAX.
Clinical TBS Thresholds (Postmenopausal Women):
Normal Microarchitecture: TBS > 1.310.
Partially Degraded: TBS 1.230 to 1.310.
Degraded: TBS < 1.230.
Whole-Body DXA and Body Composition Analysis
Whole-body DXA provides a quantitative three-compartment model of body composition:
Compartments: Measures total body Bone Mineral Content (BMC), Fat Mass (FM), and Fat-Free Lean Mass (FFM).
Visceral Adipose Tissue (VAT): Quantifies deep metabolically active abdominal fat surrounding internal organs, correlating with cardiovascular disease and insulin resistance.
Appendicular Lean Mass (ALM): Sums lean mass in arms and legs normalized to height squared (ALM/height², kg/m²) to diagnose sarcopenia and physical frailty.
Diagnostic Parameter T-Score Z-Score
Reference Population Healthy young-adult Caucasian females (ages 20–29, NHANES III) Age-, sex-, and ethnicity-matched peers
Primary Clinical Indication Postmenopausal women and men aged ≥ 50 years Premenopausal women, men aged < 50 years, and children
WHO Diagnostic Thresholds Applicable: Normal (≥ -1.0), Osteopenia (-1.1 to -2.4), Osteoporosis (≤ -2.5) Not applicable (WHO criteria cannot be used)
Diagnostic Terminology Normal, Osteopenia (Low Bone Mass), Osteoporosis "Within expected range for age" (> -2.0), "Below expected range for age" (≤ -2.0)
Clinical Action Trigger T-score ≤ -2.5 warrants osteoporosis pharmacotherapy Z-score ≤ -2.0 prompts workup for secondary osteoporosis etiologies
Genant Fracture Grade Vertebral Body Height Reduction Projected Vertebral Area Reduction Clinical Description
Grade 0 (Normal) < 20% height loss < 10% area loss Normal vertebral shape and contour; non-fractured.
Grade 1 (Mild) 20% to 25% height reduction 10% to 20% area reduction Mild wedge, biconcave, or crush deformity.
Grade 2 (Moderate) 25% to 40% height reduction 20% to 40% area reduction Moderate, clinically significant compression fracture.
Grade 3 (Severe) > 40% height reduction > 40% area reduction Severe collapse; marked structural disruption.
TBS Range Microarchitecture Classification Clinical Significance & Action
TBS > 1.310 Normal Microarchitecture Dense trabecular connectivity; baseline structural fracture protection.
TBS 1.230 to 1.310 Partially Degraded Microarchitecture Intermediate microstructural thinning; modest upward adjustment of FRAX probabilities.
TBS < 1.230 Degraded Microarchitecture High structural fragility; significant independent fracture risk; substantial upward adjustment of FRAX score.